MacroGenics reported 2.4M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbvie ABBV:US $ 4142M 121M
Amgen AMGN:US $ 1510M 51M
AstraZeneca AZN:LN 1904M 375M
Biogen BIIB:US $ 484M 269.9M
Bristol Myers Squibb BMY:US $ 2677M 206M
Daiichi Sankyo 4568:JP Y 74798M 14032M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Epizyme EPZM:US $ 5.17M 2.53M
Gilead Sciences GILD:US $ 1442M 18M
Johnson & Johnson JNJ:US $ 7919M 321M
Karyopharm Therapeutics KPTI:US $ 939K 487K
MacroGenics MGNX:US 2.4M 2.35M
Merk MRK:US $ 3698M 1636M
Pfizer PFE:US $ 8671M 1339M
Puma Biotechnology PBYI:US $ 14.92M 4.07M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Seattle Genetics SGEN:US $ 106.1M 18.47M